Anteris Technologies Global Corp (AVR)

$9.94 +0.09 (0.91%)
Market Cap 958.82M
Revenue (ttm) 1.91M
Net Income (ttm) -94.14M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -4,928.80%
Debt to Equity Ratio 0.00
Volume 2,435,900
Avg Vol 1,221,852
Day's Range N/A - N/A
Shares Out 97.34M
Stochastic %K 49%
Beta 1.78
Analysts Strong Sell
Price Target $15.80

Company Profile

Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of severe aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also develops ADAPT anti-calcification tissue, an anti-calcification preparation which transforms xenograft tissue into dura...

Industry: Medical Instruments & Supplies
Sector: Healthcare
Phone: 61 7 3152 3200
Address:
Toowong Tower, Level 3, Suite 302 9 Sherwood Road, Toowong, Australia
G101SPM
G101SPM Jul. 2 at 12:31 PM
#DILUTION Crescent Biopharma ($CBIO) files for $500 mln mixed securities shelf offering. Eastman Kodak ($KODK) files for 4,426,268 share common stock offering by selling shareholders. QXO, Inc ($QXO) files for 19,352 share common stock offering, relates to TopBuild acquisition. Anteris Technologies Global Corp. ($AVR) files for 5,385,000 share common stock offering, relates to warrants.
0 · Reply
Orlandotrader
Orlandotrader Jul. 1 at 6:16 PM
$AVR Riding the Mid Line Bollinger band
0 · Reply
Orlandotrader
Orlandotrader Jul. 1 at 6:15 PM
$AVR Very Persistent Trend!!
0 · Reply
Orlandotrader
Orlandotrader Jun. 27 at 2:50 PM
$AVR Perhaps this Improved Laminar Flow is possible with the Dura AVR Valves One Piece Construction and the Absence of Calcium Build up which is Common with the Current Three piece Valves. This company has Truly done the Painstakingly Eight year Research working with Clinicians to Build a Better Alternative.
0 · Reply
Orlandotrader
Orlandotrader Jun. 27 at 2:40 PM
$AVR What’s Really Impressive about the Dura AVR valve is the Early Data which suggests that the One Piece valve can Restore or Remodel the Left Ventricle to Normal Function. This will Truly be a New Standard. Current Valves restore Physical functionality while missing the mark on overall Native Functionality. Improving Laminar flow is a major contributing factor in this Valve Offering.
0 · Reply
Tyler_Plummer
Tyler_Plummer Jun. 25 at 2:38 AM
$AVR is about to take a skip in the matrix to $20
0 · Reply
Orlandotrader
Orlandotrader Jun. 23 at 6:11 PM
$AVR Wow!!!!! Billion dollar company. Holding Strong. Got to love this SetUp and very few posting garbage here. Loving it!!!
1 · Reply
BioTuesdays
BioTuesdays Jun. 8 at 4:55 PM
$AVR has received full regulatory clearance from the French National Agency for Medicines and Health Products Safety (ANSM) enabling patient recruitment to begin in France for the DurAVR Transcatheter Heart Valve (THV) global PARADIGM pivotal trial in patients with severe calcific aortic stenosis. https://biotuesdays.com/2026/06/08/ansm-grants-clearance-for-anteris-trial-of-transcatheter-heart-valve/
0 · Reply
double20sixteentimes
double20sixteentimes Jun. 8 at 4:54 PM
$AVR no volume. zero.
0 · Reply
EmDavis34
EmDavis34 Jun. 8 at 12:22 PM
$AVR we aren't done here!
0 · Reply
Latest News on AVR
Anteris Technologies files to sell 5.39M shares of common stock

2026-07-01T21:15:10.000Z - 15 hours ago

Anteris Technologies files to sell 5.39M shares of common stock

Anteris Technologies cleared by ANSM for DurAVR THV trial

2026-06-08T10:12:00.000Z - 24 days ago

Anteris Technologies cleared by ANSM for DurAVR THV trial

Anteris Advances Global PARADIGM Expansion with French Regulatory Clearance

Jun 8, 2026, 6:00 AM EDT - 24 days ago

Anteris Advances Global PARADIGM Expansion with French Regulatory Clearance

Anteris Technologies price target raised to $18 from $17 at Barclays

2026-05-15T08:55:46.000Z - 6 weeks ago

Anteris Technologies price target raised to $18 from $17 at Barclays

Anteris Appoints Susan Knight and Stephen Denaro to its Board of Directors

May 13, 2026, 8:39 AM EDT - 7 weeks ago

Anteris Appoints Susan Knight and Stephen Denaro to its Board of Directors

Anteris Announces Results for the First Quarter of 2026

May 12, 2026, 7:00 PM EDT - 7 weeks ago

Anteris Announces Results for the First Quarter of 2026

Anteris Technologies: First U.S. patients treated in global PARADIGM trial

2026-05-05T10:28:40.000Z - 2 months ago

Anteris Technologies: First U.S. patients treated in global PARADIGM trial

Anteris Technologies Announces First U.S. Patients Treated in Global Pivotal PARADIGM Trial

May 5, 2026, 6:00 AM EDT - 2 months ago

Anteris Technologies Announces First U.S. Patients Treated in Global Pivotal PARADIGM Trial

Anteris Technologies secures CMS reimbursement for trial site activation

2026-04-28T10:33:20.000Z - 2 months ago

Anteris Technologies secures CMS reimbursement for trial site activation

Anteris Technologies Secures CMS Reimbursement Supporting U.S. Site Activation for PARADIGM Trial

Apr 28, 2026, 6:00 AM EDT - 2 months ago

Anteris Technologies Secures CMS Reimbursement Supporting U.S. Site Activation for PARADIGM Trial

Anteris Technologies assumed with an Overweight at Cantor Fitzgerald

2026-03-12T11:35:42.000Z - 4 months ago

Anteris Technologies assumed with an Overweight at Cantor Fitzgerald

Anteris Technologies initiated with an Overweight at Wells Fargo

2026-03-11T11:01:12.000Z - 4 months ago

Anteris Technologies initiated with an Overweight at Wells Fargo

Anteris Reports 2025 Financial Results and Provides Corporate Update

Feb 26, 2026, 6:00 PM EST - 4 months ago

Anteris Reports 2025 Financial Results and Provides Corporate Update

Anteris Technologies price target lowered to $17 from $22 at Barclays

2026-02-23T14:26:31.000Z - 4 months ago

Anteris Technologies price target lowered to $17 from $22 at Barclays

Anteris Technologies price target lowered to $15 from $20 at Lake Street

2026-01-23T14:01:04.000Z - 5 months ago

Anteris Technologies price target lowered to $15 from $20 at Lake Street

MDT

Anteris Announces Strategic Investment from Medtronic to Continue Advancing TAVR in $320 Million Aggregate Capital Raises

Jan 22, 2026, 4:02 PM EST - 5 months ago

Anteris Announces Strategic Investment from Medtronic to Continue Advancing TAVR in $320 Million Aggregate Capital Raises

Anteris Technologies Global Corp. Announces Closing of $230 Million Public Offering of Common Stock

Jan 22, 2026, 4:01 PM EST - 5 months ago

Anteris Technologies Global Corp. Announces Closing of $230 Million Public Offering of Common Stock

Anteris Technologies Global Corp. Announces Pricing of $200 Million Public Offering

Jan 20, 2026, 10:53 PM EST - 5 months ago

Anteris Technologies Global Corp. Announces Pricing of $200 Million Public Offering

Anteris Technologies announces $200M common stock offering

2026-01-20T21:11:59.000Z - 5 months ago

Anteris Technologies announces $200M common stock offering

Anteris Technologies files $500M mixed securities shelf

2026-01-02T22:25:14.000Z - 6 months ago

Anteris Technologies files $500M mixed securities shelf

Anteris Technologies files to sell 9.1M shares of common stock for holders

2025-11-26T21:40:22.000Z - 7 months ago

Anteris Technologies files to sell 9.1M shares of common stock for holders

Anteris Technologies Presents Data from 100 DurAVR(R) THV Patients at PCR London

2025-11-17T11:10:50.000Z - 8 months ago

Anteris Technologies Presents Data from 100 DurAVR(R) THV Patients at PCR London

Anteris Technologies Presents Data from 100 DurAVR® THV Patients at PCR London Valves

Nov 17, 2025, 6:00 AM EST - 8 months ago

Anteris Technologies Presents Data from 100 DurAVR® THV Patients at PCR London Valves

Anteris Announces Results for the Third Quarter of 2025

Nov 12, 2025, 5:52 PM EST - 8 months ago

Anteris Announces Results for the Third Quarter of 2025

Anteris Technologies reports clinical outcomes for DurAVR THV in patients

2025-10-28T22:20:19.000Z - 8 months ago

Anteris Technologies reports clinical outcomes for DurAVR THV in patients

Anteris Technologies Announces First Patients Treated in DurAVR® THV Global Pivotal Trial (the “PARADIGM Trial”)

Oct 27, 2025, 5:43 PM EDT - 8 months ago

Anteris Technologies Announces First Patients Treated in DurAVR® THV Global Pivotal Trial (the “PARADIGM Trial”)

Anteris Technologies Announces One-Year Clinical Outcomes for DurAVR® THV to be Presented at TCT® 2025

Oct 27, 2025, 8:43 AM EDT - 8 months ago

Anteris Technologies Announces One-Year Clinical Outcomes for DurAVR® THV to be Presented at TCT® 2025

Anteris Technologies Global Corp. Announces Adjournment of Special Meeting of Stockholders

Sep 19, 2025, 2:30 AM EDT - 10 months ago

Anteris Technologies Global Corp. Announces Adjournment of Special Meeting of Stockholders

Anteris Technologies Global Corp. Announces Postponement of Special Meeting of Stockholders

Sep 11, 2025, 8:50 AM EDT - 10 months ago

Anteris Technologies Global Corp. Announces Postponement of Special Meeting of Stockholders

Anteris Announces Results for the Second Quarter of 2025

Aug 11, 2025, 4:52 PM EDT - 11 months ago

Anteris Announces Results for the Second Quarter of 2025

Anteris Appoints David Roberts and Gregory Moss to its Board of Directors

Jun 9, 2025, 10:52 PM EDT - 1 year ago

Anteris Appoints David Roberts and Gregory Moss to its Board of Directors

Anteris Technologies Reaches Clinical Milestone: 100 patients treated with DurAVR® THV

Mar 31, 2025, 7:15 AM EDT - 1 year ago

Anteris Technologies Reaches Clinical Milestone: 100 patients treated with DurAVR® THV

Anteris Reports One-Year Patient Outcomes for DurAVR® THV

Mar 21, 2025, 7:30 AM EDT - 1 year ago

Anteris Reports One-Year Patient Outcomes for DurAVR® THV

Anteris Reports 2024 Financial Results and Provides Corporate Update

Mar 12, 2025, 8:33 PM EDT - 1 year ago

Anteris Reports 2024 Financial Results and Provides Corporate Update

Anteris Technologies Global Corp. Announces Closing of $88.8 Million U.S. Initial Public Offering

Dec 16, 2024, 7:49 PM EST - 1 year ago

Anteris Technologies Global Corp. Announces Closing of $88.8 Million U.S. Initial Public Offering

Anteris Technologies Global Corp. Announces Pricing of U.S. Initial Public Offering

Dec 12, 2024, 10:34 PM EST - 1 year ago

Anteris Technologies Global Corp. Announces Pricing of U.S. Initial Public Offering

Anteris Technologies Global Corp. Announces Launch of U.S. Initial Public Offering

Dec 9, 2024, 7:43 AM EST - 1 year ago

Anteris Technologies Global Corp. Announces Launch of U.S. Initial Public Offering

G101SPM
G101SPM Jul. 2 at 12:31 PM
#DILUTION Crescent Biopharma ($CBIO) files for $500 mln mixed securities shelf offering. Eastman Kodak ($KODK) files for 4,426,268 share common stock offering by selling shareholders. QXO, Inc ($QXO) files for 19,352 share common stock offering, relates to TopBuild acquisition. Anteris Technologies Global Corp. ($AVR) files for 5,385,000 share common stock offering, relates to warrants.
0 · Reply
Orlandotrader
Orlandotrader Jul. 1 at 6:16 PM
$AVR Riding the Mid Line Bollinger band
0 · Reply
Orlandotrader
Orlandotrader Jul. 1 at 6:15 PM
$AVR Very Persistent Trend!!
0 · Reply
Orlandotrader
Orlandotrader Jun. 27 at 2:50 PM
$AVR Perhaps this Improved Laminar Flow is possible with the Dura AVR Valves One Piece Construction and the Absence of Calcium Build up which is Common with the Current Three piece Valves. This company has Truly done the Painstakingly Eight year Research working with Clinicians to Build a Better Alternative.
0 · Reply
Orlandotrader
Orlandotrader Jun. 27 at 2:40 PM
$AVR What’s Really Impressive about the Dura AVR valve is the Early Data which suggests that the One Piece valve can Restore or Remodel the Left Ventricle to Normal Function. This will Truly be a New Standard. Current Valves restore Physical functionality while missing the mark on overall Native Functionality. Improving Laminar flow is a major contributing factor in this Valve Offering.
0 · Reply
Tyler_Plummer
Tyler_Plummer Jun. 25 at 2:38 AM
$AVR is about to take a skip in the matrix to $20
0 · Reply
Orlandotrader
Orlandotrader Jun. 23 at 6:11 PM
$AVR Wow!!!!! Billion dollar company. Holding Strong. Got to love this SetUp and very few posting garbage here. Loving it!!!
1 · Reply
BioTuesdays
BioTuesdays Jun. 8 at 4:55 PM
$AVR has received full regulatory clearance from the French National Agency for Medicines and Health Products Safety (ANSM) enabling patient recruitment to begin in France for the DurAVR Transcatheter Heart Valve (THV) global PARADIGM pivotal trial in patients with severe calcific aortic stenosis. https://biotuesdays.com/2026/06/08/ansm-grants-clearance-for-anteris-trial-of-transcatheter-heart-valve/
0 · Reply
double20sixteentimes
double20sixteentimes Jun. 8 at 4:54 PM
$AVR no volume. zero.
0 · Reply
EmDavis34
EmDavis34 Jun. 8 at 12:22 PM
$AVR we aren't done here!
0 · Reply
Dockyy
Dockyy Jun. 5 at 10:53 AM
$AVR Never forget Medtronic owns 15% of this. This unique valve will bring their arsenal equal or better to Edwards Sapien. I follow this because I need a valve, and want this one. Done my DD. Am invested
1 · Reply
EmDavis34
EmDavis34 Jun. 5 at 3:29 AM
$MX another stock I'm smacking around is $AVR I'm heavy on $10 June 18th calls. This will touch $11 tomorrow on no news. Depending on premarket, calls will probably open around .60, gonna grab 20 or 30.
0 · Reply
Spicy_Trade
Spicy_Trade Jun. 5 at 2:24 AM
Anteris Technologies Global Cor ( $AVR ) SpicyTrade - Daily Stock Analysis https://youtu.be/0U8m0ds4VBs?si=VKXPeEnEt59IIUKi
0 · Reply
EmDavis34
EmDavis34 Jun. 4 at 11:05 PM
$AVR over 10 👀👀
0 · Reply
EmDavis34
EmDavis34 Jun. 4 at 8:54 PM
$AVR this will be over $10.50 tomorrow, same with $MX over $10
0 · Reply
hankbb02
hankbb02 Jun. 4 at 5:35 PM
$AVR this isnt a stock you trade, its a deep small cap value
3 · Reply
QuantInsider
QuantInsider Jun. 4 at 4:31 PM
$AVR popping off today, up around 6% and 9% over the last five days Traders are hitting those short-dated $10 calls hard Looks like the options market is betting on more upside Watch out, volatility is already high so this is a momentum play with some risk Saw a big sweep of 1,957 Jun 18 $10 calls, about 4.5 times the prior open interest Price busted through $10 so keep an eye on that level It's a key spot for support or failure before diving into any new bullish moves
0 · Reply
Olivia_Strickland
Olivia_Strickland Jun. 4 at 3:12 PM
$AVR poppin 8.2% to 9.68 but only 0.35x avg vol, so the crowd isn't really here for it. these thin breakouts can reverse on you quick once the few buyers tap out. chart's doing the talking, no headline on my feed. where you think this fades or follows through? on my swing list now: https://tapeboard.com/scanner?utm_source=stocktwits&utm_medium=post&utm_campaign=olivia&utm_content=avr-bk-up-watch&utm_term=scanner&s=AVR
0 · Reply
ApexEquityVault
ApexEquityVault Jun. 4 at 2:40 PM
$AVR gamma squeeze don’t miss it
0 · Reply
ApexEquityVault
ApexEquityVault Jun. 4 at 2:39 PM
$AVR 10 Call 6/18 here 🚨
0 · Reply
ApexEquityVault
ApexEquityVault Jun. 4 at 2:39 PM
High Confidence 🚨 $AVR 10 Call 6/18 at 0.60
0 · Reply
ApexEquityVault
ApexEquityVault Jun. 4 at 2:39 PM
$AVR 10 Call 6/18 at 0.60
0 · Reply